WO2002038126A2 - Procede de production de particules pour preparations pharmaceutiques presentant une biodisponibilite accrue - Google Patents

Procede de production de particules pour preparations pharmaceutiques presentant une biodisponibilite accrue Download PDF

Info

Publication number
WO2002038126A2
WO2002038126A2 PCT/DK2001/000715 DK0100715W WO0238126A2 WO 2002038126 A2 WO2002038126 A2 WO 2002038126A2 DK 0100715 W DK0100715 W DK 0100715W WO 0238126 A2 WO0238126 A2 WO 0238126A2
Authority
WO
WIPO (PCT)
Prior art keywords
hpmcas
particle
particles
core
active compound
Prior art date
Application number
PCT/DK2001/000715
Other languages
English (en)
Other versions
WO2002038126A3 (fr
Inventor
Ove Emil Hansen
Original Assignee
Aeromatic-Fielder Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeromatic-Fielder Ag filed Critical Aeromatic-Fielder Ag
Priority to AU2002212102A priority Critical patent/AU2002212102A1/en
Publication of WO2002038126A2 publication Critical patent/WO2002038126A2/fr
Publication of WO2002038126A3 publication Critical patent/WO2002038126A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Definitions

  • the present invention relates to a process for production of particles for pharmaceutical compositions having increased bioavailability and a particle obtainable according to said process.
  • a dosis form which may be a tablet, capsule or the like
  • the pharmaceutical active compound of the dosage form generally enters the blood through a mucosa or the gastro-intestinal channel. In most instances, it is not the entire administered amount of pharmaceutical active compound which is actually absorbed by the body. Various reasons may be the cause for this lack of absorption, including low solubility of the active compound in the relevant body fluid, the dosage form and the fed state of the patient. If the active compound has a poor solubility in the relevant body fluid, the bioavailability is low due to the fact that the active compound to cross the mucosa or the gastric- intestine channel generally has to be in a solubili- zed state.
  • a solubility enhancer or the increment of the amorphisity.
  • the amorphisity can be increased by dissolving the pharmaceutical active compound in a solvent and subsequently rapidly evaporate the sol- vent.
  • the amorphisity can also be enhanced by providing the compound as an amorphous dispersion in a suitable solid carrier, such as a polysaccharide.
  • the present invention is directed to the improvement of the bioavailability of a pharmaceutical active compound by providing the pharmaceutical active compound as a solid dispersion in a derivative of a polysaccharide.
  • the present is directed to the dispersion of a pharmaceutical active compound in hydroxypropylmethylcellulose acetate succinate (HPMCAS) .
  • HPMCAS hydroxypropylmethylcellulose acetate succinate
  • US patent No. 4,983,593 discloses a solvate of the drug NZ-105 and HPMCAS.
  • the solvate can be prepared into 'tablets, capsules, granules, and powders, which exhibit an enhanced bioavailability of the drug.
  • methods for preparation of the solid solvate it is suggested to remove the solvent from a solution of NZ-105 and HPMCAS by means of vacuum- drying or freeze-drying.
  • EP 0 901 786 A2 discloses a composition comprising a dispersion of a sparingly water-soluble drug in HPMCAS.
  • the dispersion is prepared by spray drying a solution of the sparingly water-soluble drug and HPMCAS to form particles with an average diameter less than 100 ⁇ m.
  • the spray drying process involves atomizing a solution which comprises the sparingly water-soluble drug, HPMCAS and a suitable solvent into a plurality of small droplets and subsequent removing the solvent from said droplets. It is demonstrated that a supersaturation is obtained for a number of compounds. However, in the examples, a tendency of the supersaturation not to remain stabile is observed as the degree of supersaturation decreases with time.
  • the present invention pertains to a process for production of particles for pharmaceutical compositions having increased bio- availability, comprising the steps of: a) providing a solution or dispersion comprising hydroxypropylmethylcellulose acetate succinate
  • HPMCAS and a sparingly water-soluble pharmaceutical active compound in an evaporable liquid
  • layering a core with one or more deposit (s) comprising HPMCAS and a sparingly water-soluble pharmaceutical active compound by i) spraying said solution or dispersion onto a core particle suspended in a gas in a chamber, ii) evaporating the liquid of the solution or dispersion to obtain, on the core particle, a deposit comprising the HPMCAS and the sparingly water-soluble pharmaceutical active compound, and iii) renewed treatment in accordance with step i) and ii) of the core particle provided with the deposit until a predetermined particle size or weight is obtained, and c) recovering the particles.
  • a particle which is obtainable in accordance with the above process.
  • a particle which comprises a core and a layer comprising a solid dispersion of a sparingly water-soluble pharmaceutical active compound in a matrix of hydroxypropylmethylcellulose acetate succinate (HPMCAS)
  • the pharmaceutical active compound may be any sparingly water-soluble compound having a pharmaceutical activity, i.e compounds showing therapeutic and/or prophylactic properties when administered to a subject.
  • the term sparingly water- soluble pharmaceutical compound refers herein to a compound which is essentially totally water-insoluble or poorly water-soluble. More specifically, a sparingly water-soluble pharmaceutical compound, as used herein, refers to a compound having a dosage to aqueous solubility greater that 100ml, preferably greater than 500ml, where the aqueous solubility is measured in unbuffered water.
  • the pure pharmaceutical active compound can be crystalline or amorphous at normal temperatures and pressures. However, the advantages of the present invention is predominantly obtained for compounds that tend to be crystalline at ambient temperatures and pressures.
  • HPMCAS generally refers to a family of cellulose derivatives that can have (1) two types of ether substituents, methyl and/or 2-hydroxypropyl or (2) two types of ester substituents, acetyl and/or succinyl.
  • HPMCAS is referred to in the scientific literature as 0- (2-hydroxypropyl) -O-methyl-cellulose acetate succinate.
  • the degree of substitution for each of the four general types just noted can be varied over a wide range to effect the chemical and physical properties of the polymer.
  • the versatility of HPMCAS allows its structure to be optimized to obtain good performance with a particular pharmaceutical compound of interest. HPMCAS can be purchased commercially.
  • HPMCAS Three examples of commercially available HPMCAS products include Shin- Etsu AQOAT ® -LF, Shin-Etsu AQOAT ® -MF and Shin-Etsu AQ0AT ® -HF. All three of these polymers are manufactured by Shin-Etsu Chemical Co., Ltd. (Tokyo) .
  • the specific grade that yields the best performance for obtaining and maintaining supersaturation varies depending on the specific chemical and physical properties of the pharmaceutical compound to be delivered.
  • a preferred mean weight average molecular weight range for HPMCAS is 10,000 to 400,000 daltons, as determined using polyethylene oxide standards .
  • HPMCAS is insoluble in water and gastric fluid but soluble in aqueous base, such as solutions containing sufficient base to have a pH of 6.5 or greater following dissolution of HPMCAS.
  • the proportion of pharmaceutical active compound to HPMCAS can be within a wide range.
  • the weight ratio of pharmaceutical active compound to HPMCAS can be between 1 to 0,2 and 1 to 100.
  • the actual proportion used can easily be determined by the person skilled in the art and depend largely on the nature of the pharmaceutical compound used. In some cases is it preferred that the ratio of pharmaceutical active compound to HPMCAS is between 1 to 1 and 1 to 50.
  • the layering technique used in the present invention effects rapid solvent removal so that crystallization of the pharmaceutical active compound and HPMCAS is largely prevented or at least minimized relative to processes involving solvent removal in a less rapid fashion, such as rotary evaporation.
  • the present invention provides a process in which the pharmaceutical active compound is efficiently dispersed in a matrix of HPMCAS.
  • the pharmaceutical active compound is molecularly dispersed in the HPMCAS matrix, however, a minor amount of local crystallization in the HPMCAS can be accepted.
  • the solution or dispersion comprising HPMCAS and the pharmaceutical compound may contain further components if so desired.
  • the solution can contain polymers other than HPMCAS that are soluble in the relevant body fluid.
  • Such further polymers include matrix materials such as polyvinyl- pyrolidone, hydroxypropylcellulose and hydroxypropylmethylcellulose .
  • a surfactant can also be included in the solution to increase the rate of dissolution of the resulting particle by facilitating wetting and also to inhibit crystallization or precipitation of the pharmaceutical active compound.
  • surfactants which may be used are fatty acids, alkyl sulfo- nates, benzethanium chloride, polyoxyethylene sorbi- tan fatty acid esters (Tween) , sodium taurocholic acid, l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholi- ne, lecithin, and other phospholipids and mono- and diglycerides .
  • pH modifiers can be acids, bases or puffers. pH modifiers can serve to enhance the dissolution rate for certain pharmaceutical compounds which are more soluble at a specific pH range.
  • the further components may or may not be fully dissolved in the liquid prior to the layering step.
  • the liquid for the solution or dispersion in step a) can be any liquid having the ability to dissolve the pharmaceutical compound and swell or dissolve HPMCAS sufficiently to provide a solution or dispersion which is sufficiently stable.
  • the liquid must be sufficient evaporable to allow for an essential removal of liquid during step b) ii) to produce a solidified layer.
  • the liquid is non- aqueous and able to provide a true solution of the HPMCAS and the pharmaceutical active compound.
  • a suitable liquid has a boiling point of 150°C or less. The choice of liquid depends on the nature of the components.
  • Suitable liquids are alcohols (methanol, ethanol, n-propanol, iso-propanol, and butanol) , ketones (methyl ethyl ketone, acetone, methyl iso- butyl ketone) , esters (ethyl acetate, propyl acetate) , and various other evaporable liquids such as acetonitril, methylene chloride, toluene, and 1,1,1- trichloroethane . A mixture of two or more liquids may also be used for the solution.
  • the amount of liquid in the solution can vary within a broad range. Generally, due to process economy, it is desired not to use liquid in a large excess but to use what is needed to provide for a sufficient solution or dispersion. Furthermore, the attached examples tend to show that a more rapid dissolution of the pharmaceutical compound from the final particles results from a solution having a minor amount of liquid relative to a solution having an excess amount of liquid.
  • the solution or dispersion in step a) is suitably provided by dissolving or swelling the HPMCAS in the solvent and subsequently adding the pharmaceutical active compound under constant stirring. Howe- ver, the method for providing the solution or dispersion is not critical for the invention.
  • the cores to be layered with one or more deposit (s) comprising HMPCAS and the pharmaceutical active compound can be pharmaceutically active or pharmaceutically inert.
  • a pharmaceutically active core comprises at least one compound with beneficial prophylactic and/or therapeutic properties when administered to a human or animal subject.
  • the pharmaceutical active compound optionally comprised by the core can be the same compound as the pharmaceutical compound contained in the layer or it can be a different pharmaceutical compound which can be administered simultaneously or subsequent to the administering of the pharmaceutical compound contained in the deposit (s).
  • a pharmaceutically inert core has substantially no impact on the treated disease of the human or animal body.
  • the pharmaceutical inert core can comprise a disintegrating agent which will cause the layered particle to disrupt in the relevant body fluid.
  • the pharmaceutical inert core can also be a solid particle or object, which does not disintegrate in the relevant body fluid.
  • the pharmaceutical inert core is mainly intended for carrying the layers comprising HPMCAS and the pharmaceutical compound, but the particle or object may have other porposes. Examples of core materials are glass, lactose, micro- crystalline cellulose, HPMCAS, and starch.
  • the cores may have any shape, size, and size distribution suitable for the production of the desired layered particle. To obtain a uniform final product it is generally desired to use cores with a narrow size distribution.
  • the core may be an agglomerate, a granule, or a particle which has been layered with one or more layer (s) in accordance with the invention. Agglomerates and granules can be made by any method conventionally used in the art, such as spray-drying, vacuum-drying, or spray-granulation. I the event that a particle which has been layered with a layer is used as the core material, such previous prepared layer can contain pharmaceutical active compounds different from or identical to the pharmaceutical active compound incorporated in the layer around this core material.
  • the cores which optionally can be layered one or more times, are sprayed with the solution or dispersion comprising HPMCAS and the pharmaceutical active compound in a chamber.
  • the spraying is usually effected by a two fluid or three fluid nozzle while the cores are suspended in a gas.
  • the nozzle can be placed in the top, side walls or the bottom of the spraying chamber and the chamber can be provided with more than one nozzle. It is however, preferred that the nozzle is provided in the bottom to obtain a more even and accurate distribution of the solution on the cores. The best yield is obtained when the direction of the droplets ejected from the nozzle is substantially equal to the direction of the moving cores.
  • the core particles may be suspended in the gas in any convenient manner. It is, however, preferred that the core particle is carried upwards from the bottom of the spraying chamber by a suitable stream of gas. The gas suspended core particles are then hit by one or more small droplets ejected from the nozz- le. Subsequent to the spraying step, the liquid of the solution provided on the core particles is evaporated to obtain, on the core, a deposit comprising HPMCAS and the pharmaceutical active compound. It is preferred that the chamber in which the spraying is effected also is used for the evaporation of the liquid.
  • the cores are moved through the spraying zone for performing step b) i) to an evaporation zone for performing step b) ii) by the gas in which the cores are suspended. Furthermore, is it preferred that the gas velocity is high enough to convey the particles out of the chamber .
  • the gas in which the cores are suspended is drying gas.
  • the liquid is evaporated.
  • the spraying method is referred to is the rest of the description as co-current spraying.
  • the use of co-current spraying has the advantage that the drying can be effected rapidly as the essential drying is done during the relative short period of time the particle is in the upper part of the chamber. It is generally acknowledged, that the degree of amorphisity increases when the evaporation is accelerated, probably due to less time for the individual molecules to arrange in a crystalline form.
  • the particles may be subjected to a renewed treatment in accordance with step b) i) and b) ii) immediately or the particles may be stored in an interim period before renewed treatment.
  • the layered particles are stored, it is preferred to store the particles in a compartment adjoining the drying chamber in the same container to allow for a communication between the storage compartment and the spraying chamber. It is preferred slightly to aerate the particles when stored to evaporate any remaining amount of evaporable liquid and to avoid adherence between neigh- bouring particles.
  • An improvement of the preferred co-current spraying embodiment can be obtained if the drying gas performs a swirling movement when carrying the particles upwards.
  • the swirl in the chamber is essential laminar to avoid non-uniform coating.
  • the swirling causes the particles to move upwards without the occurrence of partial plugging or pulsating or catchy movement through the cloud of atomized solution or dispersion.
  • a preferred apparatus for conducting the process according to the present invention is disclosed in EP 0 741 603 Bl (Aeromatic- Fielder AG) , the content of which is incorporated herein by reference.
  • WO 00/40339 Another apparatus which can be used for practi- sing the present invention is disclosed in WO 00/40339 (Aeromatic-Fielder AG) .
  • the cores are initially moved by an upward flow of drying gas and subsequently sprayed with the solution or dispersion which is atomized in a two-fluid or three-fluid nozzle.
  • the drying gas is supplemented with a muffling gas which impedes the scattering effect of the atomizing gas.
  • the entire disclosure of WO 00/40339 is included herein by reference .
  • the treatment of the layered particles in step b) continues until a predetermined particle size or weight is obtained.
  • the determination of the desired particle size or weight can be conducted in accordance with known classification procedures.
  • a predetermined amount of cores is sprayed with a predetermined amount of solution to produce the particles with the desired particle size or weight.
  • the particles produced in accordance with the process of the present invention can be formulated into a pharmaceutical composition using methods conventional within the art.
  • Preferred dosage forms are for oral use. Examples of such dosage forms are tablets, capsules, powders, granulates, cachets, and pills.
  • Various additives can be mixed, ground, or granulated with the particles produced according to the invention to form a material which is suitable for the production of the dosage form.
  • additives are matrix materials, fillers and diluents such as lactose, mannitol, xylitol, microcrystalline cellulose, calcium diphosphate, and starch; surfactants such as lauryl sulfate, and polysorbate 80; complex binding agents or solubilizers such as polyethylene glycols, caffeine, xanthene, and cyclodex- trins; disintegrating agents such as sodium starch glycolate, sodium alginate, carboxymethyl cellulose, and methyl cellulose; binders such as methyl cellulose, microcrystalline cellulose, starch, guar gum, and tragacant; lubricants such as magnesium stearate and calcium stearate; and pH modifiers such as acids (e.g.
  • citric acid acetic acid, ascorbic acid, lactic acid, aspartic acid, succinic acid, and phosphoric acid
  • bases e.g. sodium acetate, potassium acetate, calcium oxide, magnesium oxide, trisodium phosphate, 5. sodium hydroxide, and aluminium hydroxide
  • buffers which generally comprise a mixture of an acid or base with the corresponding salt.
  • the particles produced in accordance with the present invention show a rapid disso- 0 lution rate and an ability to produce a supersaturation in a duodenal mimicing fluid.
  • the supersaturation in the disclosed examples is more than 2 times the normal equilibum concentration for the pharmaceutical active compound.
  • the supersaturation 5 is stable in the time span of the analysis (1200 min) , that is, no decrease in the amount of dissolved pharmaceutical active compound is observed.
  • the dissolution rate can be altered by altering the ratio of core amount 0 to solution or dispersion comprising HPMCAS and pharmaceutical active compound.
  • an increased dissolution rate may be obtained by increasing the amount of core material relative to the amount of 5 solution or dispersion comprising HPMCAS and a pharmaceutical active compound. This effect is probably obtained due to an increased surface area exposed to the duodenal mimicing fluid. This observation makes is possible to design a pharmaceutical composition 0 with a controlled release profile.
  • the core material was selected as glass beads to allow for visual inspection of the produced particles in an optical microscope.
  • the size of the glass beads was 0.5 mm.
  • 1500 g of core material was loaded into the PRECISION COATERTM in the storing compartment. The apparatus was started and the core material was brought to the operating temperature of 75°C.
  • the feed material was sprayed from the bottom with a 2-fluid nozzle at a rate of 30-32 ml/min using compressed air at 6 bar and a temperature of 75 °C.
  • Run 1 was stopped when 12 kg of feed material 1 was used and the Run 2 was continued until all feed material 2 was sprayed onto the cores.
  • the ratio of core amount to phenytoin in the first run was higher than the amount in the second run.
  • the layered particles were visually inspected in a optical microscope and a coherent film was observed covering the core particle.
  • the dissolution of the layers deposited on the cores produced in Run 1 and 2 was tested and compared to a reference of crystalline phenytoin.
  • a sample was accurately weighed into an empty microcentrifuge tube and 1,8 ml of a phosphate buf- fered saline solution [(8.2mM NaCl, 1.1 mM Na 2 HP0 4 , 4.7mM KH 2 P0 4 , pH 6.5, 290 mOsm/kg) containing 14.7 mM sodium tauocholic acid (Fluka) and 2.8mM 1-palmitoyl- 2-oleoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids)] was added to the tube.
  • the phosphate buf- fered saline solution mimics the duodenal fluid.
  • TMC theoretical maximum concentration
  • the centrifuge tube was closed and a timer was started. The content of the tube was then stirred continuously at the highest speed of a vortex mixer
  • Each sample was diluted with a solution containing 60/40 1.7 % by weight aqueous ammonium aceta- te/acetonitril. This solution used for the dilution was also used as the mobile phase for the subsequent HPLC analysis.
  • the concentration of compound was determined by HPLC using a Phenomenex Ultracarb (ODS 20) analytical column. The absorbance was measured at 215 nm with a diode array spectrometer. The measured concentration of compound is indicated in table II.
  • the gain factor is calculated as the concentration of active compound after 1200 min divided with the concentration of the reference after 1200 min. Table II:
  • the reference was crystalline phenytoin which was placed in excess in a centrifuge tube together with 1.8ml of the phosphate buffered saline solution. The reference was tested in the same way as the samples. After an initial higher concentration, the soluble amount of phenytoin in the phosphate buffered saline solution stabilizes at a concentration of about 68 ⁇ g/ l. This value is considered as the normal saturation point.
  • the dissolution rate of Run 1 is about twice the dissolution rate of Run 2 within the first 60 min. It is hypothesised that the increased dissolution rate in run 1 is due to an increased surface area and a thinner layer of phenytoin and HMPCAS. This observation makes is possible to design a pharmaceutical composition with a controlled release profile. According to the results, a faster disso- lution rate for a certain dosage can be obtained if the ratio of core to phenytoin is increased.
  • An Aeromatic-Fielder, PRECISION COATERTM PM-1 was used for the layering of cores of spherical microcrystalline cellulose , obtained from Cellphere ® , and having a size of 0 . 5 mm. Feed materials prepared using the procedure described in example 1 , and with the composition shown in table III were used .
  • 890g of the core material was loaded onto the PRECISION COATERTM in each of the two runs with feed material 3 and feed material 4, respectively.
  • the apparatus was started and the core material was brought to the operating temperature of 75°C.
  • the feed material was sprayed from the bottom with a 2-fluid nozzle at a rate of 30-32 ml/min using compressed air at 6 bar and a temperature of 75 °C. All feed material was used for layering the cores.
  • the supersaturation is more than twice the normal saturation for the layered particle produced from the solution having a low content of solids (feed material 3) and more than 3 times the normal saturation for the layered particle produced from the solution having a high content of solids (feed material 4) .
  • the dissolution rate in the initial 60 min is higher for the layered particle produced in run 4. It is believed that the increased amount of solvent in feed solution 3 allows for a less degree of amorphisity because more time is available for orientation of the individual species. It is also interesting to observe that the supersaturation is stable in the time span of the analysis, that is, no decrease in the amount of dissolved phenytoin is observed.
  • a comparison between the result of example 1 and the present example shows that the material of the core may be of importance for the gain factor.
  • the particles produced in Run 2 and 4 respecti- vely, is compared, it is evident that particles having a core of microcrystalline cellulose have a more rapid dissolution profile compared to the particle of Run 2 having a core of glass.
  • solvent during the dissolution test penetrates the layer of phenytoin and HPMCAS and swells the core material, thus increasing the total surface area either by breaking the particle and disrupting the layer or by simply enlarging the particle.
  • a feed material 5 was. produced by dissolving 270 g of HPMCAS (Shin-Etsu AQOAT ® -MF manufactured by Shin-Etsu Chemical Co., Ltd. (Tokyo)) in 29700 g of acetone under stirring at room temperature (20 °C) . To this solution 30 g of Phenytoin was added under constant stirring. The stirring was continued until all Phenytoin was dissolved.
  • HPMCAS Shin-Etsu AQOAT ® -MF manufactured by Shin-Etsu Chemical Co., Ltd. (Tokyo)
  • the entire amount of feed material was sprayed onto the glass beads from the bottom with a 2-fluid nozzle at a rate of 30-32 ml/min using compressed air at 6 bar and a temperature of 75 °C.
  • the sample amount of the layered particles produced in run 5 was selected in the higher area to obtain a TMC which was well above the reference concentration to be able to study the highest possible gain factor. As indicated in table V, a gain factor as high as 3.8 was obtained. Moreover, the supersaturation was stable in the observed time span, indicated by the constant increase in the measured concentration of the phenytoin.

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé de production de particules pour une préparation pharmaceutique présentant une biodisponibilité accrue. Ce procédé comprend la vaporisation d'un noyau doté d'une solution ou d'une dispersion comprenant du succinate acétate hydroxypropylméthylcellulose (HPMCAS) et un composant actif pharmaceutique modérément soluble dans l'eau dans un liquide évaporable, l'évaporation du liquide afin d'obtenir un dépôt de HPMCAS et des composants actifs pharmaceutiques modérément solubles dans l'eau soluble, puis répétition du procédé jusqu'à l'obtention d'une taille ou d'un poids de particule prédéterminé.
PCT/DK2001/000715 2000-11-08 2001-10-29 Procede de production de particules pour preparations pharmaceutiques presentant une biodisponibilite accrue WO2002038126A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002212102A AU2002212102A1 (en) 2000-11-08 2001-10-29 A process for production of particles for pharmaceutical compositions having increased bioavailability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70796600A 2000-11-08 2000-11-08
US09/707,966 2000-11-08

Publications (2)

Publication Number Publication Date
WO2002038126A2 true WO2002038126A2 (fr) 2002-05-16
WO2002038126A3 WO2002038126A3 (fr) 2002-10-10

Family

ID=24843867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2001/000715 WO2002038126A2 (fr) 2000-11-08 2001-10-29 Procede de production de particules pour preparations pharmaceutiques presentant une biodisponibilite accrue

Country Status (2)

Country Link
AU (1) AU2002212102A1 (fr)
WO (1) WO2002038126A2 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159626A1 (fr) * 2010-06-14 2011-12-22 Bend Research, Inc. Acétosuccinate d'hydroxypropylméthylcellulose avec substitution acétate et succinate améliorée
US8268349B2 (en) 2003-08-28 2012-09-18 Abbott Laboratories Solid pharmaceutical dosage form
US20120264833A1 (en) * 2004-05-28 2012-10-18 Babcock Walter C Pharmaceutical compositions with enhanced performance
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8470347B2 (en) 2000-05-30 2013-06-25 AbbVie Deutschland GmbH and Co KG Self-emulsifying active substance formulation and use of this formulation
US8883206B2 (en) 2012-02-27 2014-11-11 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US9139530B2 (en) 2005-12-28 2015-09-22 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9402851B2 (en) 2003-11-27 2016-08-02 Bayer Intellectual Property Gmbh Process for the preparation of a solid, orally administrable pharmaceutical composition
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10662192B2 (en) 2004-06-24 2020-05-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0344603A1 (fr) * 1988-05-30 1989-12-06 Zeria Pharmaceutical Co., Ltd. Composition pharmaceutique contenant un dérivé de la dihydropyridine
WO1993000991A1 (fr) * 1991-07-03 1993-01-21 Smithkline Beecham Plc Procede de preparation de substances medicamenteuses sous forme de granules
WO1995020432A1 (fr) * 1994-01-27 1995-08-03 Aeromatic-Fielder Ag Dispositif d'enrobage de particules solides
EP0901786A2 (fr) * 1997-08-11 1999-03-17 Pfizer Products Inc. Dispersions solides pharmaceutiques à biodisponibilité accrue
US5985322A (en) * 1997-05-29 1999-11-16 Eli Lilly And Company Method for the treatment of CNS disorders
WO2000040339A1 (fr) * 1998-12-30 2000-07-13 Aeromatic-Fielder Ag Appareil et procede d'enrobage de comprimes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0344603A1 (fr) * 1988-05-30 1989-12-06 Zeria Pharmaceutical Co., Ltd. Composition pharmaceutique contenant un dérivé de la dihydropyridine
WO1993000991A1 (fr) * 1991-07-03 1993-01-21 Smithkline Beecham Plc Procede de preparation de substances medicamenteuses sous forme de granules
WO1995020432A1 (fr) * 1994-01-27 1995-08-03 Aeromatic-Fielder Ag Dispositif d'enrobage de particules solides
US5985322A (en) * 1997-05-29 1999-11-16 Eli Lilly And Company Method for the treatment of CNS disorders
EP0901786A2 (fr) * 1997-08-11 1999-03-17 Pfizer Products Inc. Dispersions solides pharmaceutiques à biodisponibilité accrue
WO2000040339A1 (fr) * 1998-12-30 2000-07-13 Aeromatic-Fielder Ag Appareil et procede d'enrobage de comprimes

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470347B2 (en) 2000-05-30 2013-06-25 AbbVie Deutschland GmbH and Co KG Self-emulsifying active substance formulation and use of this formulation
US8268349B2 (en) 2003-08-28 2012-09-18 Abbott Laboratories Solid pharmaceutical dosage form
US8691878B2 (en) 2003-08-28 2014-04-08 Abbvie Inc. Solid pharmaceutical dosage form
US8309613B2 (en) 2003-08-28 2012-11-13 Abbvie Inc. Solid pharmaceutical dosage form
US8333990B2 (en) 2003-08-28 2012-12-18 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8399015B2 (en) 2003-08-28 2013-03-19 Abbvie Inc. Solid pharmaceutical dosage form
US9402851B2 (en) 2003-11-27 2016-08-02 Bayer Intellectual Property Gmbh Process for the preparation of a solid, orally administrable pharmaceutical composition
US9415053B2 (en) 2003-11-27 2016-08-16 Bayer Intellectual Property Gmbh Solid, orally administrable pharmaceutical composition
US20120264833A1 (en) * 2004-05-28 2012-10-18 Babcock Walter C Pharmaceutical compositions with enhanced performance
US8940800B2 (en) * 2004-05-28 2015-01-27 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
US10662192B2 (en) 2004-06-24 2020-05-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US11291662B2 (en) 2005-12-28 2022-04-05 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9139530B2 (en) 2005-12-28 2015-09-22 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9931334B2 (en) 2005-12-28 2018-04-03 Vertex Pharmaceuticals Incorporated Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US10537565B2 (en) 2005-12-28 2020-01-21 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US11564916B2 (en) 2008-08-13 2023-01-31 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
EP2579896B1 (fr) 2010-06-14 2016-07-20 Dow Global Technologies LLC Acétosuccinate d'hydroxypropylméthylcellulose avec substitution acétate et succinate améliorée
WO2011159626A1 (fr) * 2010-06-14 2011-12-22 Bend Research, Inc. Acétosuccinate d'hydroxypropylméthylcellulose avec substitution acétate et succinate améliorée
US9040033B2 (en) 2010-06-14 2015-05-26 Dow Global Technologies Llc Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution
CN103153343A (zh) * 2010-06-14 2013-06-12 陶氏环球技术有限责任公司 具有提高的醋酸酯和琥珀酸酯取代的醋酸羟丙基甲基纤维素琥珀酸酯
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11147770B2 (en) 2012-02-27 2021-10-19 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8883206B2 (en) 2012-02-27 2014-11-11 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11752106B2 (en) 2012-02-27 2023-09-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Also Published As

Publication number Publication date
AU2002212102A1 (en) 2002-05-21
WO2002038126A3 (fr) 2002-10-10

Similar Documents

Publication Publication Date Title
AU612591B2 (en) Pharmaceutical formulations comprising microcapsules
CZ280884B6 (cs) Farmaceutický přípravek
WO2002038126A2 (fr) Procede de production de particules pour preparations pharmaceutiques presentant une biodisponibilite accrue
EP1291014A1 (fr) Procédé de fabrication d'une préparation pharmaceutique solide contenant une substance médicamenteuse à faible solubilité
PT92616B (pt) Processo para a preparacao de granulados para composicoes orais de particulas multiplas de libertacao controlada
WO1989002738A1 (fr) Preparation de nifedipine a liberation soutenue
WO2022081814A1 (fr) Formulations de cannabinoïdes inhalables
US20140030346A1 (en) Disintegrable core particle for pharmaceutical preparation
JPH0776517A (ja) 医薬用組成物
UA82532C2 (uk) Спосіб виготовлення капсул флуконазолу з покращеним вивільненням
EP0850048B1 (fr) Granules pharmaceutiques
WO2006074066A1 (fr) Formulation non cristalline comprenant du clopidogrel
EP1701702A1 (fr) Procede d'atomisation/congelation faisant appel a une extrudeuse pour la preparation de compositions d'azithromycine multiparticulaires contenant de preference un poloxamere et un glyceride
EP0636023B1 (fr) Procede de sechage par pulverisation d'aminoguanidine
TWI270380B (en) Azithromycin multiparticulate dosage forms by liquid-based processes
US20050152982A1 (en) Controlled release multiparticulates formed with dissolution enhancers
Liu et al. Polymer‐coated microparticles for the sustained release of nitrofurantoin
CA2182024C (fr) Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
Gandhi et al. Formulation and Evaluation of Microballoons of Ramipril
HRP940557A2 (en) Process for the preparation of ceruroxime axetil as pharmaceutical preparation
MXPA06006265A (en) Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP